ftInvstr
MEDICO · Healthcare ₹39.52 -0.23% Mkt Cap ₹327 Cr

MEDICO

Healthcare Drug Manufacturers - Specialty & Generic
₹39.52
-0.23% today · 30d -17.34%
as of 2026-09-04
Price · Daily Candles
“MEDICO sees impressive Q4 profit surge as FIIs quietly increase stake, but long-term growth forecasts lag.”
MEDICO reported a robust Q4 2026 with net profit growing 34.92% YoY to ₹6 Cr, and revenue up 37.54% YoY to ₹57 Cr. This strong quarterly performance contributes to an annual net profit CAGR of 38.32% over five years. However, ML predictions for future EBIT and sales growth range from weak to neutral, indicating potential headwinds despite current momentum.
BULL CASE
+Q4 2026 revenue increased 37.54% YoY to ₹57 Cr, demonstrating strong top-line expansion.
+Net profit in Q4 2026 surged 34.92% YoY to ₹6 Cr, signaling improved profitability.
+The company has shown a 5-year Net Profit CAGR of 38.32%, indicating sustained historical growth.
+FIIs increased their holding by 0.05% QoQ in Q1 2027, reaching 0.08%.
BEAR CASE
ML predictions for 1-year EBIT growth are neutral, with ranks of 0.468 (recent 2yr), 0.451 (rolling 4yr), and 0.447 (stable 7yr).
Sales growth predictions are weak to neutral, with a rank of 0.373 for recent 2-year and 0.424 for stable 7-year.
The stock is trading at a PE (TTM) of 30.72, which is higher than peers like LUPIN (20.43) and ZYDUSLIFE (21.85).
Current FCF of ₹6 Cr yields 1.49%, and ML models predict severe negative FCF compression in the near future.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹57 Cr
+37.54% YoY
NET PROFIT
₹6 Cr
+34.92% YoY
OPM
16.8%
+0.07pp YoY
EPS
₹0.71
PE 30.72
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-50.0%, h2=-50.0%, h3=-50.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
MEDICO's TTM PE of 30.72 positions it above ZYDUSLIFE (21.85) and LUPIN (20.43) but below SUNPHARMA (38.41) and DIVISLAB (82.02), while its profitability score is rated high (75).
PEERPEROCE %
MEDICO30.72
SUNPHARMA38.4121.44
DIVISLAB82.0221.56
CIPLA35.1218.37
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
54
SCORE / 100
Overall
6-axis composite of the sections below.
Performance POSITIVE 55
Valuation FAIR 40
Growth STRONG 75
Profitability HIGH 75
Technicals WEAK 30
Risk MODERATE 50
Key Stats
TTM PE
30.72
P/B
5.3
52W HIGH
₹56.88
OFF HIGH
-30.52%
MKT CAP
₹327 Cr
◉ Active Signals
MACDBearish-0.5284
RSI(14)Bearish38.36
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold MEDICO and at what entry.

Sign up freeSign in